^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASTX295

    i
    Other names: ASTX295, ASTX 295, ASTX-295
    Associations

    News

    Trials
    Company:
    Otsuka
    Drug class:
    MDM2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=106, Active, not recruiting, Taiho Oncology, Inc. | N=250 --> 106
    Enrollment change • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification
    |
    ASTX295
    5ms
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=250, Active, not recruiting, Taiho Oncology, Inc. | Trial primary completion date: Dec 2024 --> May 2024
    Trial primary completion date • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    ASTX295
    1year
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=250, Active, not recruiting, Astex Pharmaceuticals, Inc. | Trial primary completion date: Jun 2025 --> Dec 2024
    Trial primary completion date • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification
    |
    ASTX295
    over1year
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=250, Active, not recruiting, Astex Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification
    |
    ASTX295
    over2years
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=250, Recruiting, Astex Pharmaceuticals, Inc. | N=191 --> 250 | Trial completion date: May 2023 --> Aug 2025 | Trial primary completion date: Apr 2023 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification
    |
    ASTX295
    over3years
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=191, Recruiting, Astex Pharmaceuticals, Inc. | Active, not recruiting --> Recruiting
    Clinical • Enrollment open
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    ASTX295
    over3years
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=191, Active, not recruiting, Astex Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    ASTX295
    over3years
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=191, Recruiting, Astex Pharmaceuticals, Inc. | N=135 --> 191
    Clinical • Enrollment change
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    ASTX295
    over4years
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=135, Recruiting, Astex Pharmaceuticals, Inc. | Active, not recruiting --> Recruiting
    Clinical • Enrollment open
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    ASTX295
    almost5years
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (clinicaltrials.gov)
    P1/2, N=135, Active, not recruiting, Astex Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    ASTX295